Immunotherapy for Alzheimer’s disease
The DOI matches its Crossref record.
Abstract
A primary goal of research on Alzheimer's disease is to develop disease modifying therapeutics. The amyloid cascade hypothesis has focused the initial efforts on methods to reduce amyloid. One surprising approach that has shown considerable success in mouse models and has hinted at benefits in human trials is anti-Abeta immunotherapy. Schenk first showed the amyloid reducing potential of active immunization in 1999. This prompted our group and that of St. George-Hyslop to investigate whether active immunization would similarly retard the memory deficits that develop in amyloid depositing transgenic mice. Contrary to our initial predictions of premature memory dysfunction due to inflammation, vaccination protected amyloid depositing mice from developing memory deficits. Subsequent studies found that passive immunization could reverse memory deficits, even when administered for short periods. These encouraging findings led to a trial of an Abeta vaccination in Alzheimer patients. The trial was cut short due to meningoencephalitic symptoms in 6% of patients, yet, in a subset of patients, those developing brain reactive antibodies benefited from slower rates of cognitive decline. These observations have accelerated the development of passive immunization protocols and safer vaccines. At this time, anti-amyloid immunotherapy stands poised to be the first test of the amyloid hypothesis in the treatment of Alzheimer disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As previously anticipated, passive immunotherapy is considered the most effective approach to preventing and treating AD (see Figure 1) [36,37].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [37]
Citations
Cites
Still being checked.
Cited by
Behavioral phenotyping strategies for mutant mice
Crawley, J. N. (2008) · Neuron · doi:10.1016/j.neuron.2008.03.001 · Cited by 439
Animal Models of Alzheimer Disease
LaFerla, F. M., & Green, K. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006320 · Cited by 419
Transgenic mouse models of Alzheimer’s disease.
Elder, G. A., Gama Sosa, M. A., & De Gasperi, R. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20159 · Cited by 336
Relevance of Transgenic Mouse Models to Human Alzheimer Disease
Morrissette, D. A., Parachikova, A., Green, K. N., & LaFerla, F. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800030200 · Cited by 147
Scholtzova, H., Kascsak, R. J., Bates, K. A., Boutajangout, A., Kerr, D. J., Meeker, H. C., Mehta, P. D., Spinner, D. S., & Wisniewski, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5715-08.2009 · Cited by 166
Retracted: ‘Clinical trials in Alzheimer’s disease’: immunotherapy approaches
Delrieu, J., Ousset, P. J., Caillaud, C., & Vellas, B. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07458.x · Cited by 139
RetractedAlzheimer 100 – highlights in the history of Alzheimer research
Jellinger, K. A. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0578-3 · Cited by 159
Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies
Valera, E., & Masliah, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.013 · Cited by 132
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Pharmacogenomics in Alzheimer's Disease
Cacabelos, R. (2008) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-205-2_10 · Cited by 109
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
“As previously anticipated, passive immunotherapy is considered the most effective approach to preventing and treating AD (see Figure 1) [36,37].”
BackgroundTargeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
Kang, I., Jeon, Y. E., Yin, X. F., Nam, J., You, S. G., Hong, M. S., Jang, B. G., & Kim, M.-J. (2011) · Food and Chemical Toxicology · doi:10.1016/j.fct.2011.06.023 · Cited by 71
Kayed, R., & Jackson, G. R. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.05.001 · Cited by 62
Perfusion Magnetic Resonance Imaging in Psychiatry
Théberge, J. (2008) · Topics in Magnetic Resonance Imaging · doi:10.1097/rmr.0b013e3181808140 · Cited by 56
New therapeutic targets in atrophic age-related macular degeneration
Petrukhin, K. E. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.5.625 · Cited by 55
Nitric oxide‐mediated regulation of ‐amyloid clearance via alterations of MMP‐9/TIMP‐1
Ridnour, L. A., Dhanapal, S., Hoos, M., Wilson, J., Lee, J., Cheng, R. Y. S., Brueggemann, E. E., Hines, H. B., Wilcock, D. M., Vitek, M. P., et al. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12028 · Cited by 54
Alzheimer's Disease: Another Target for Heparin Therapy
Bergamaschini, L., Rossi, E., Vergani, C., & De Simoni, M. G. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.100 · Cited by 47
A limited role for microglia in antibody mediated plaque clearance in APP mice
García-Alloza, M., Ferrara, B. J., Dodwell, S. A., Hickey, G. A., Hyman, B. T., & Bacskai, B. J. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.019 · Cited by 50
Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?
Foster, J. K., Verdile, G., Bates, K. A., & Martins, R. N. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.115 · Cited by 47
Iurascu, M. I., Cozma, C., Tomczyk, N., Rontree, J. A., Desor, M., Drescher, M., & Przybylski, M. (2009) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-009-3164-3 · Cited by 46
Nanoliposomes as a Therapeutic Tool for Alzheimer’s Disease
Ordóñez-Gutiérrez, L., & Wandosell, F. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00020 · Cited by 32
Kang, I., Jang, B. G., In, S., Choi, B., Kim, M., & Kim, M.-J. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2012.09.013 · Cited by 39
Amyloid beta peptide immunotherapy in Alzheimer disease
Delrieu, J., Ousset, P., Voisin, T., & Vellas, B. J. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.10.003 · Cited by 39
Immunology meets neuroscience – Opportunities for immune intervention in neurodegenerative diseases
Lynch, M. A., & Mills, K. H. G. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.05.013 · Cited by 37
Vaccine Development to Treat Alzheimer’s Disease Neuropathology in APP/PS1 Transgenic Mice
Carrera, I., Etcheverría, I., Fernández‐Novoa, L., Lombardi, V., Cacabelos, R., & Vigo, C. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/376138 · Cited by 32
Medecigo, M., Manoutcharian, K., Vasilevko, V., Govezensky, T., Munguía, M. E., Becerril, B., Luz-Madrigal, A., Vaca, L. A., Cribbs, D. H., & Gevorkian, G. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.03.023 · Cited by 32
Treatment of Alzheimer’s disease
Tsai, P., & Cummings, J. L. (2016) · Cambridge University Press eBooks · doi:10.1017/9781139924771.025 · Cited by 30
Solórzano-Vargas, R. S., Vasilevko, V., Acero, G., Ugen, K. E., Martinez, R., Govezensky, T., Vázquez‐Ramírez, R., Kubli‐Garfias, C., Cribbs, D. H., Manoutcharian, K., et al. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.08.008 · Cited by 25
Xu, J., Barger, S. W., & Drew, P. D. (2008) · PPAR Research · doi:10.1155/2008/349185 · Cited by 24
Vlad, C., Iurascu, M. I., Slamnoiu, S., Hengerer, B., & Przybylski, M. (2012) · Methods in molecular biology · doi:10.1007/978-1-4614-3704-8_27 · Cited by 22
Carrera, I., Etcheverría, I., Li, Y., Fernández‐Novoa, L., Lombardi, V., Vigo, C., Palacios, H. H., Benberin, V. V., Cacabelos, R., & Aliev, G. (2013) · BioMed Research International · doi:10.1155/2013/709145 · Cited by 23
Chaperone-Like Antibodies in Neurodegenerative Tauopathies: Implication for Immunotherapy
Kontseková, E., Ivanovova, N. P., Handzusova, M., & Novák, M. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9355-9 · Cited by 21
Li, Q.-Y., Gordon, M. N., Chackerian, B., Alamed, J., Ugen, K. E., & Morgan, D. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9183-1 · Cited by 20
Self-citationAshwini, P., Bodhankar, S. L., Muthal, A., Kumar, D., Pawar, A., & Kulkarni, R. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.11.016 · Cited by 19
Okura, Y., Kohyama, K., Park, I.-K., & Matsumoto, Y. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31818b48db · Cited by 15
¿Es factible la vacunación contra la encefalopatía espongiforme transmisible?
Wısnıewskı, T., Chabalgoity, J. A., & Goñi, F. (2007) · Scientific and Technical Review (World Organisation for Animal Health) · doi:10.20506/rst.26.1.1739 · Cited by 15
Combination therapy prevents amyloid-dependent and -independent structural changes
Malthankar‐Phatak, G. H., Poplawski, S. G., Toraskar, N., & Siman, R. G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.007 · Cited by 12
Wang, C.-M., deVries, S., Camboni, M., Glass, M., & Martin, P. T. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.013 · Cited by 11
Jang, B.-G., Choi, B., Kim, S., Lee, D.-S., Lee, J., Koh, Y. H., Jo, S. A., Kim, J., Kang, T., & Kim, M.-J. (2022) · Cells · doi:10.3390/cells11162585 · Cited by 5
Amyloid‐β concentration and structure influences the transport and immunomodulatory effects of IVIG
Wuest, D., & Lee, K. H. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12678 · Cited by 5
Biotinylated Microbubbles Targeted to Amyloid
Rand, A., Gilman, G., O’Kane, D. J., & Bëlohlávek, M. (2008) · The Open Clinical Chemistry Journal · doi:10.2174/1874241600801010075 · Cited by 4
Petre, B. A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-06068-2_7 · Cited by 4
Jung, J. E., Cárdenas, V., & Petre, B. A. (2023) · European Journal of Mass Spectrometry · doi:10.1177/14690667231199012 · Cited by 1
Haddad, J. J. (2007) · Technische Universität Dortmund Eldorado (Technische Universität Dortmund) · doi:10.17877/de290r-7331 · Cited by 1
cu, M.-I. I., Cozma, C., Langridge, J., Tomczyk, N., Desor, M., & Przybylski, M. (2010) · CRC Press eBooks · doi:10.1201/b10460-19 · Cited by 1
Alzheimer’s Disease—is it Caused by Cerebrovascular Dysfunction?
Humpel, C. (2009) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195326697.003.0015 · Cited by 1
Pharmacogenomics and Personalized Medicine in Alzheimer’s Disease
Archer, T., & Johansson, B. E. A. (2013) · Springer eBooks · doi:10.1007/978-81-322-1184-6_15 · Cited by 1
Antibodies in Phase III Studies for Immunological Disorders
Ward, P., & Bodmer, M. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch29
Wuest, D. (2014) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/w8v4-sd45
Neural networks in a mouse model of amyloid pathology
Palmer, A. M. (2012) · ORCA Online Research @Cardiff (Cardiff University)
Regenerating the brain: Stem cell differentiation and cholinergic dysfunction in Alzheimer disease
Malmsten, L. (2014) · Figshare
Evaluating a new drug to combat alzheimer's disease.
Sibiya, S. G. (2014) · ResearchSpace (University of KwaZulu-Natal)
Intracellularly selected recombinant antibodies targeting β Amyloid Oligomers
Meli, G. (2007) · SDL
Inter-relação entre doença periodontal e déficit cognitivo em ratos Wistar
Ribas, M. E. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Tratamento Homeopático da Disfunção Cognitiva Canina - Relato de Caso
de Azevedo, R. B. D. A., do Amaral, M. S., & da Silva, A. M. M. (2022) · Editora Conhecimento Livre eBooks · doi:10.37423/2022.edcl555
Tratamiento de la enfermedad de Alzheimer
Golimstok, Á. (2006) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/rev.hosp.ital.b.aires.v26i4.1128
Metadata
- Authors
- Morgan, D.
- Affiliations
- Alzheimer Research Laboratory, Department of Pharmacology and Molecular Therapeutics, University of South Florida, Tampa, FL, USA
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2006-07-27
- Volume
- 9
- Issue
- s3
- Pages
- 425-432
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2272671729
- Cited by
- 50
- References
- 0
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 3 · 2020: 1 · 2016: 1 · 2014: 5 · 2013: 3 · 2012: 5
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG018478, AG 15490, R01AG015490, AG18478)
- National Institute of Neurological Disorders and Stroke (NS48335, R01NS048335)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, immunotherapy
- MeSH terms
- Alzheimer Disease, Humans, Immunotherapy, Vaccination, Immunotherapy, Active, Amyloid beta-Protein Precursor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.